Co-Authors
This is a "connection" page, showing publications co-authored by Vincent Gendrin and Thierry Conrozier.
Connection Strength
0.681
-
Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Clin Exp Rheumatol. 2020 Jul-Aug; 38(4):742-747.
Score: 0.222
-
Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia. Infect Dis Ther. 2021 Sep; 10(3):1195-1213.
Score: 0.060
-
Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'. Ann Rheum Dis. 2021 Jun 23.
Score: 0.060
-
Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials. Rev Med Virol. 2022 01; 32(1):e2239.
Score: 0.059
-
Is There Still a Place for Tocilizumab in Coronavirus Disease 2019? Open Forum Infect Dis. 2021 Feb; 8(2):ofab013.
Score: 0.058
-
Coronavirus disease 2019 with spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema, France. New Microbes New Infect. 2020 Nov; 38:100785.
Score: 0.057
-
Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020 Oct; 99:491-495.
Score: 0.056
-
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19). Microbes Infect. 2020 10; 22(9):500-503.
Score: 0.056
-
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020 Aug; 50(5):397-400.
Score: 0.055